Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results

Cancer Genetics and Cytogenetics

Volumn 191, Issue 1, 2009, Pages 1-9

  Holzerová, Milena ^a   Faber, Edgar ^a   Veselovská, Jitka ^b   Urbánková, Helena ^a   Balcárková, Jana ^a   Rožmanová, Šárka ^a   Voglová, Jaroslava ^c   Mužík, Jan ^d   Chroust, Karel ^d   Indrák, Karel ^a   Jarošová, Marie ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYTARABINE; ETOPOSIDE; IDARUBICIN; IMATINIB;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEMALE; FOLLOW UP; GENE DELETION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TRISOMY 8;

ADOLESCENT; ADULT; AGED; CHROMOSOME ABERRATIONS; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 64649102342     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.12.013     Document Type: Article

References (31)

1. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., and Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med 341 (1999) 164-172
2. De Braekeleer M. Variant Philadelphia translocations in chronic myeloid leukemia. Cytogenet Cell Genet 44 (1987) 215-222
3. Calabrese G., Stuppia L., Guanciali Franchi P., Peila R., Morizio E., Liberati A.M., Spadano A., Di Lorenzo R., Donti E., Antonicci A., and Palka G. Complex translocations of the Ph chromosome and Ph negative CML arise from similar mechanisms, as evidenced by FISH analysis. Cancer Genet Cytogenet 78 (1994) 153-159
4. Albano F., Specchia G., Pannunzio A., Roberti M.G., Buquicchio C., Mestice A., Greco G., and Liso V. Variant t(9;22) translocation may identify a subgroup of chronic myeloid leukemia patients with poor prognosis. Blood 98 (2001) 321a (Abstract)
5. Heisterkamp N., Jenster G., ten Hoeve J., Zovich D., Pattengale P.K., and Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 344 (1990) 251-254
6. Lugo T.G., Pendergast A.M., Muller A.J., and Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247 (1990) 1079-1082
7. Hochhaus A., Druker B., Sawyers C., Guilhot F., Schiffer C.A., Cortes J., Niederwieser D.W., Gambacorti-Passerini C., Stone R.M., Goldman J., Fischer T., O'Brien S.G., Reiffers J.J., Mone M., Krahnke T., Talpaz M., and Kantarjian H.M. Favorable long-term follow-up results over 6 years response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood 111 (2008) 1039-1043
8. Johansson B., Fioretos T., Billström R., and Mitelman F. Aberrant cytogenetic evaluation pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-α. Leukemia 10 (1996) 1134-1138
9. Terre C., Eclache V., Rousselot P., Imbert M., Charrin C., Gervais C., Mozziconacci M.J., Maarek O., Mossafa H., Auger N., Dastugue N., Talmant P., Van den Akker J., Leonard C., N'Guyen Khac F., Mugneret F., Viguié F., Lafage-Pochitaloff M., Bastie J.N., Roux G.L., Nicolini F., Maloisel F., Vey N., Laurent G., Recher C., Vigier M., Yacouben Y., Giraudier S., Vernant J.P., Salles B., Roussi J., Castaigne S., Leymarie V., Flandrin G., and Lessard M. France Intergroupe pour la Leucémie Myéloïde Chronique. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18 (2004) 1340-1346
10. Cortez J.E., Talpaz M., Giles F., O'Brien S., Rios M.B., Shan J., Garcia-Manero G., Faderl S., Thomas D.A., Wierda W., Ferrajoli A., Jeha S., and Kantarjian H.M. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101 (2003) 3794-3800
11. O'Shea D., Crotty G., Carroll P., Conneally E., McCann S., and Neat M.J. Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance?. Br J Haematol 127 (2004) 367-369
12. Schoch C., Haferlach T., Kern W., Schnittger S., Berger U., Hehlmann R., Hiddemann W., and Hochhaus A. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 17 (2003) 461-463
13. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., and Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
14. Huntly B.J., Bench A., and Green A.R. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 102 (2003) 1160-1168
15. Huntly B.J., Reid A.G., Bench A.J., Campbell L.J., Telford N., Shepherd P., Szer J., Prince H.M., Turner P., Grace C., Nacheva E.P., and Green A.R. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98 (2001) 1732-1738
16. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., Apperley J., Cervantes F., Cortes J., Deininger M., Gratwohl A., Guilhot F., Horowitz M., Hughes T., Kantarjian H., Larson R., Niederwieser D., Silver R., and Hehlmann R. European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukaemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
17. Jarosová M., Holzerová M., Mihál V., Lakomá I., Divoký V., Blazek B., Pospísilová D., Hajdúch M., Novák Z., Dusek L., Koptíková J., Poulsen T.S., and Indrák K. Complex karyotypes in childhood acute lymphoblastic leukemia: cytogenetic and molecular cytogenetic study of 21 cases. Cancer Genet Cytogenet 145 (2003) 161-168
18. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J.M., Cavé H., Pane F., Aerts J.L., De Micheli D., Thirion X., Pradel V., González M., Viehmann S., Malec M., Saglio G., and van Dongen J.J. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia 17 (2003) 2318-2357
19. Willis S.G., Lange T., Demehri S., Otto S., Crossman L., Niederwieser D., Stoffregen E.P., McWeeney S., Kovacs I., Park B., Druker B.J., and Deininger M.W. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106 (2005) 2128-2137
20. Quintas-Cardama A., Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Verstovsek S., Rios M.B., Hayes K., Glassman A., Bekele B.N., Zhou X., and Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105 (2005) 2281-2286
21. Markovic V.D., Bouman D., Bayani J., Al-Maghrabi J., Kamel-Reid S., and Squire J.A. Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. Leukemia 14 (2000) 1157-1160
22. Quintas-Cardama A., Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Verstovsek S., Rios M.B., Hayes K., Glassman A., Bekele B.N., Zhou X., and Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105 (2005) 2281-2286
23. Oudat R., Khan Z., and Glassman A.B. Detection of trisomy 8 in Philadelphia chromosome-positive CML patients using conventional cytogenetic and interphase fluorescence in situ hybridization techniques and its relation to c-myc involvement. Ann Clin Lab Sci 31 (2001) 68-74
24. Mohamed A.N., Pemberton P., Zonder J., and Schiffer C.A. The effect on imatinib mesylate on patients with Philadelphia chromosome positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res 9 (2003) 1333-1337
25. Alimena G., De Cuia M.R., Diverio D., Gastaldi R., and Nanni M. The karyotype of blastic crisis. Cancer Genet Cytogenet 26 (1987) 39-50
26. O'Dwyer M.E., Gatter K.M., Loriaux M., Druker B.J., Olson S.B., Magenis R.E., Lawce H., Mauro M.J., Maziarz R.T., and Braziel R.M. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 17 (2003) 481-487
27. - cells in chronic myeloid leukemia: evidence of secondary origin of the Ph chromosome?. Br J Haematol 135 (2006) 265-266
28. Gozzetti A., Tozzuoli D., Crupi R., Gentili S., Bocchia M., Raspadori D., and Lauria F. Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy of imatinib mesylate (STI). Eur J Haematol 71 (2003) 313-314
29. Lin Y., Bruyère H., Horsman D.E., Pantzar T., Barnett M.J., Hogge D.E., Nevill T.J., Nantel S.H., Sutherland H.J., Toze C.L., Shepherd J.D., Lavoie J.C., Song K.W., Smith C.A., and Forrest D.L. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet 170 (2006) 16-23
30. Symeonidis A., Marinakis T., Papaioannou M., Panayiotidis P., Kouraklis-Symeonidis A., Pantelidou D., Zouvelou C., Roussou P., Verrou E., Tsatalas C., Anagnostopoulos N., and Zoumbos N. The significance of aberrant cytogenetic clones, emerging during treatment of chronic myelogenous leukemia with imatinib mesylate. Haematologica 92 Suppl. 1 (2007) 467 (Abstract 1289)
31. Babicka L., Zemanova Z., Pavlistova L., Brezinova J., Ransdorfova S., Houskova L., Moravcova J., Klamova H., and Michalova K. Complex chromosomal rearrangements in patients with chronic myeloid leukemia. Cancer Genet Cytogenet 168 (2006) 22-29